Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
Bone Therapeutics would also issue and automatically allot one subscription right to each outstanding share of Bone Therapeutics, in case of statistically positive interim results of the ALLOB Phase IIb trial.
Lead Product(s): Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bone Therapeutics
Deal Size: $5.0 million Upfront Cash: $5.0 million
Deal Type: Acquisition August 10, 2022
Details:
ALLOB (allogeneic bone cell therapy) represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells.
Lead Product(s): Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2022
Details:
BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow, is to be injected by a physician into the patient’s damaged disc to Treat Chronic Lumbar Disc Disease.
Lead Product(s): BRTX-100
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BRTX-100
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2022
Details:
BRTX-100 is a novel product to treat damaged, degenerating discs, an autologous stem cell product to treat persistent lower back pain due to painful degenerative discs.
Lead Product(s): BRTX-100
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BRTX-100
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
The proceeds of the financing will contribute to continuing to advance the clinical development of Bone Therapeutics’ lead asset, its allogeneic bone cell therapy, ALLOB.
Lead Product(s): Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ABO Securities
Deal Size: $5.4 million Upfront Cash: Undisclosed
Deal Type: Agreement May 31, 2022
Details:
The proceeds of the financing will be used to advance the clinical development of Bone Therapeutics’ lead asset, the allogeneic bone cell therapy, ALLOB.
Lead Product(s): Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ABO Securities
Deal Size: $5.4 million Upfront Cash: Undisclosed
Deal Type: Financing April 12, 2022
Details:
Pursuant to the agreement, PRC Clinical will manage BioRestorative’s Phase 2 clinical study of BRTX-100, the Company’s lead clinical product to treat chronic lumbar disc disease.
Lead Product(s): Hypoxic Cultured Mesenchymal Stem Cells
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BRTX-100
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: PRC Clinical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 21, 2021
Details:
Milvexian demonstrated efficacy and no increase in bleeding across doses, when compared with enoxaparin, for postoperative venous thromboembolism (VTE) prevention in patients undergoing elective total knee replacement (TKR) surgery.
Lead Product(s): Milvexian
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: JNJ-70033093
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Janssen Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
Allay intends to proceed into a Phase 2b study of ATX-101 in total knee arthroplasties (TKA, also called total knee replacements) in the United States.
Lead Product(s): Bupivacaine
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ATX-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Arboretum Ventures
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 15, 2021
Details:
Catalent has purchased the shares of SCTS and a purpose-built CGxP facility of approximately 41,000 square-foot. Catalent will undertake the manufacturing of clinical material for Bone Therapeutics’ drug, ALLOB, an allogeneic osteoblastic cell therapy product.
Lead Product(s): ALLOB
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 16, 2020
